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OVERVIEW
Multiple sclerosis (MS) is a complex,
debilitating, immunopathologic disease of
the human central nervous system (CNS)
characterized by chronic systemic inflam-
mation, alterations in innate-immune sig-
naling, progressive demyelination and
axonal loss. Currently there is no effec-
tive treatment or cure for MS. Recent data
indicate that common molecular-genetic
mechanisms involving a select group of
NF-kB-sensitive microRNAs are shared
by most MS patients, and their mech-
anism of pathogenic action is becom-
ing increasingly understood. This brief
“Opinion” paper will highlight some
recently clarified roles for two NF-kB-
regulated, pro-inflammatory microRNAs,
miRNA-146a and miRNA-155, in the MS
disease process. We will also advance
an opinion on how anti-NF-kB, anti-
miRNA and/or related therapeutic strate-
gies may be beneficial in the clinical
management of MS and other progres-




To understand the contribution of
miRNA-146a and miRNA-155 to the
etiopathogenesis of MS we will briefly
highlight some salient features of this
autoimmune disease. MS is globally the
most common immunopathologic disor-
der affecting the human CNS: (i) with
about 2.5 million affected worldwide
(approximately 30 cases/100,000 glob-
ally; http://www.nationalmssociety.org/);
(ii) with a variable incidence of fre-
quency in different regions of the world
(Melcon et al., 2014); (iii) with a variable
incidence of occurrence amongst differ-
ent human populations (Høglund and
Maghazachi, 2014); (iv) with significant
heterogeneity in the clinical pheno-
type (Sturm et al., 2014; http://www.
nationalmssociety.org/); and (v) with low
concordance rates in monozygotic twins,
suggesting the involvement of complex
heritable, epigenetic, microbial and/or
environmental factors (Küçükali et al.,
2014; Ma et al., 2014; Melcon et al., 2014).
MS is generally characterized by abnormal
responses of the immune system directed
against glial-derived CNS myelin which
normally sheaths, insulates and protects
axons and nerve bundles (Küçükali et al.,
2014; Melcon et al., 2014). MS exhibits (i)
“sclerotic” or lipoprotein-enriched scar tis-
sue nodules associated with demyelinated
axons where normal electrical activi-
ties become progressively disorganized
(Baranzini, 2014; Küçükali et al., 2014);
and (ii) a wide variety of clinical symptoms
that include muscle weakness, spastic-
ity, loss of balance, sensory deficit and
fatigue, dizziness, and vertigo, bowel, blad-
der and visual problems, depression and
cognitive and psychiatric changes; approx-
imately 90% of MS individuals become
ultimately disabled (Baranzini, 2014; Guo
et al., 2014; Harris and Sadiq, 2014).
Consistent observations at the pathogenic
and molecular-genetic level indicate five
main highly interactive characteristics of
MS: (i) a progressive demyelination whose
extent correlates to MS severity; (ii) axonal
swelling and macrophage activation; (iii)
a T-cell mediated inflammatory response
that subsequently triggers immune cells
to release pro-inflammatory cytokines
such as IL-1β; (iv) permeability changes
in the blood–brain barrier (Kamphuis
et al., 2015); and (v) increases in pro-
inflammatory microRNA and related
pathogenic biomarkers (Haghikia et al.,
2012; Meinl and Meister, 2012; Danborg
et al., 2014; Harris and Sadiq, 2014;
Küçükali et al., 2014; Ma et al., 2014;
Sturm et al., 2014; Kamphuis et al.,
2015; see below). Specific gene mutations
linked to MS include a cluster at human
chromosome 6, part of the so-called
“autoimmunome” network, which serves
as the major histocompatibility complex
(MHC) locus; interestingly this genetic
locus is also implicated in the autoim-
mune disease type 1 diabetes and systemic
lupus erythematosis (Baranzini, 2014;
Gourraud et al., 2014; Sturm et al., 2014).
Epidemiological evidence collectively indi-
cates that MS is an immunopathologic
disorder initiated by exogenous factors
including microbes, possibly of viral ori-
gin, vaccines or unknown environmental
factors in susceptible individuals geneti-
cally predisposed for MS (Gilden, 2005;
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Küçükali et al., 2014; Ma et al., 2014;
Sturm et al., 2014). Indeed, heterogeneity
in the MS clinical course and low twin
concordance rates implicate multiple,
complex, environmental and epigenetic
factors that contribute to MS pathogenesis
andmost recently, a potential contribution
by inducible species of CNS microRNAs
(Haghikia et al., 2012; Lopez-Ramirez
et al., 2014; Ma et al., 2014; Zhang et al.,




Human CNS microRNAs (miRNAs)
constitute a family of about 2050,
20–23 nucleotide non-coding single
stranded RNAs (ssRNAs) that regulate
the expression of their target mRNAs
post-transcriptionally, and have impor-
tant roles in development, differentiation,
aging, autoimmunity and neurodegener-
ation (Lukiw et al., 2008; Cui et al., 2010;
Guo et al., 2010; O’Connell et al., 2010; Li
et al., 2011; Zhang et al., 2014; Zhao et al.,
2014).
One major mode of action in the
CNS is for inducible, up-regulated miR-
NAs to decrease their target mRNA levels
and hence decrease gene expression (Cui
et al., 2010; Guo et al., 2010). Concurrent
induction of both NF-kB (p50/p65) and
pro-inflammatory miRNAs in stressed
human primary brain cells has identified
a group of pathogenic miRNAs under NF-
kB (p50/p65) transcriptional control and
these include miRNA-146a and miRNA-
155 (Lukiw, 2012a; Zhang et al., 2014;
Zhao et al., 2014). Interestingly, these same
miRNAs have been found to be increased
in sporadic Alzheimer’s disease (AD) tis-
sues which exhibit (i) significant global
up-regulation of NF-kB in AD-affected
anatomical regions (Lukiw and Bazan,
1998; Lukiw, 2012b); (ii) down-regulation
in the expression of innate-immune mark-
ers such as the IL-1β receptor-associated
kinase 1 (IRAK-1; with a concurrent
surge in IRAK-2; Cui et al., 2010); and
(iii) a progressive inflammatory degen-
eration (Latta et al., 2014). Different
species of pro-inflammatory miRNAs in
different CNS compartments may con-
tribute to similar degenerative pathologies
- for example miRNA-146a and miRNA-
155 have slightly different effects on
inflammatory gene expression in human
brain and retina (see below; Lukiw et al.,
2012; Ma et al., 2014). It is also impor-
tant to point out that there appears to
be some heterogeneity in miRNA abun-
dance, complexity and related biomark-
ers amongst different human populations
with the same neurological disorder, how-
ever recent evidence suggests important
common, underlying pathogenic roles for
miRNA-146a and miRNA-155 throughout
theMS disease process (Meinl andMeister,
2012; Kutty et al., 2013; Harris and Sadiq,
2014; Ma et al., 2014).
miRNA-146A AND INFLAMMATORY
DEGENERATION
Few CNS-resident miRNAs have gained so
much interest as an inducible “potentially
pathogenic miRNA” implicated in NF-
kB-mediated pro-inflammatory signaling
and aberrant activation of the innate-
immune response as has miRNA-146a,
in a surprisingly wide variety of progres-
sive, neurodegenerative CNS disorders.
These include AD, MS, and prion-, neu-
rotropic virus- and metal-sulfate-induced
neurological dysfunctions (Taganov et al.,
2006; Lukiw et al., 2008; Hill et al., 2009;
Pogue et al., 2009; Cui et al., 2010; Saba
et al., 2012; Kutty et al., 2013; Ma et al.,
2014). The 22 nucleotide miRNA-146a
(5′-UGAGAACUGAAUUCCAUGGGUU-
3′; 59% A + U; NCBI Gene ID: 406938),
encoded at human chromosome 5q33.3
is a rapidly induced, pro-inflammatory
miRNA with a relatively short half-life of
about 1.5–2 h in human CNS cells and
tissues (Sethi and Lukiw, 2009). miRNA-
146a was originally described as being
significantly up-regulated after micro-
bial endotoxin, lipopolysaccharide or
cytokine stimulation of myeloid cells and
under transcriptional control by NF-κB;
shortly thereafter this inducible miRNA-
146a was found to be up-regulated by
metal sulfate-generated reactive oxygen
species, by pro-inflammatory cytokines
(such as IL-1β and TNFα) and by Aβ42
peptides in human primary brain cells
(Taganov et al., 2006; Lukiw et al., 2008;
Hill et al., 2009; Pogue et al., 2009; Cui
et al., 2010). Further, miRNA-146a tar-
gets the 3′-UTR of mRNAs encoding
signaling proteins involved in the innate
immune and inflammatory response,
including complement factor H (CFH)
and IRAK-1, and both compartmental-
ized CFH and IRAK-1 deficiencies are
observed in MS (Taganov et al., 2006; Cui
et al., 2010; Ingram et al., 2014; Stürner
et al., 2014). Interestingly, significant
amounts of miRNA-146a have been found
in glial cells responsible for axonal myeli-
nation (Li et al., 2011; Alexandrov et al.,
2014; Kroesen et al., 2015). Of further
interest is that viral infections of brain
cells by herpes simplex virus 1 (HSV-1;
Herpesviridae; Group 1 dsDNA) and other
neurotrophic viruses both up-regulate
NF-kB and miRNA-146a, and induce
pathogenic events that can be quenched
using antiviral drugs such as acyclovir
(Hill et al., 2009; Lukiw et al., 2010).
miRNA-155 AND
NEURODEGENERATIVE DISEASE
The 23 nucleotide miRNA-155 (5′-
UUAAUGCUAAUCGUGAUAGGGGU-3′;
61% A + U; NCBI: AF402776) encoded in
humans at chr 21q21.3 is an inducible
miRNA under transcriptional control
by NF-kB (p50/p65; Lukiw et al., 2012;
Lu et al., 2013). miRNA-155, strongly
and rapidly up-regulated by inflamma-
tory cytokines, is highly expressed within
lymphocytes (both B and T cells) and
its role in adaptive and innate immunity
has also been strengthened by recent evi-
dence (Lukiw, 2012a,b; Lopez-Ramirez
et al., 2014; Seddiki et al., 2014). Specific
up-regulation of miRNA-155 is observed
in related immunopathologic conditions
including MS, Down’s syndrome (trisomy
21), rheumatoid arthritis and systemic
lupus erythematosus where it affects
both T lymphocyte and blood-brain bar-
rier functions (Junker, 2011; Leng et al.,
2011; Li et al., 2012; Lopez-Ramirez
et al., 2014; Kamphuis et al., 2015).
Compared to controls miRNA-155 is the
only miRNA commonly increased in MS
brain, spinal cord lesions and in periph-
eral blood mononuclear cells (PBMC;
Ma et al., 2014). Interestingly, in exper-
imental autoimmune encephalomyelitis
(EAE), a mouse model for MS, miRNA-
155 expression has been shown to increase
significantly in the spleen, lymph node
and brain as EAE progresses, and miRNA-
155(–/–) mice exhibit resistance to EAE
and significantly less CNS inflammation
(Murugaiyan et al., 2011; Thamilarasan
et al., 2012). Both miRNA-146a (see
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above) and/or miRNA-155: (i) target
the CD47 3′-UTR, promoting down-
regulation of CD47 on brain resident
cells, triggering the macrophage-mediated
phagocytosis of myelin (Junker et al.,
2009) and/or (ii) induce the development
of IFN-γ-producing T helper type 1 (Th1)
cell subsets and CD4(+) T cells that secrete
interleukin (IL)-17 (Th17 cells); these cells
are known to induce inflammatory degen-
eration in MS, psoriasis, autoimmune
uveitis and rheumatoid arthritis (Ma et al.,
2014; Seddiki et al., 2014; Stürner et al.,
2014). Very recently it has been shown
that (i) suppressing miRNA-155 expres-
sion inhibits the development of Th1
and Th17 cells, resulting in the decrease
of disease severity in EAE (Zhang et al.,
2014); and (ii) anti-miRNA-155 treat-
ment in EAE significantly inhibits EAE
development (Murugaiyan et al., 2011;
Ma et al., 2014; Seddiki et al., 2014). As
miRNA-155 is encoded on chr21q21.3,
the extra gene dosage of chromosome 21
in trisomy 21 patients is associated with
(i) increased miRNA-155 levels; (ii) pro-
inflammatory signaling and deficits in
the innate immune response; and (iii) an
increased incidence of autoimmune dis-
ease with cognitive disabilities (Lu et al.,
2008; Li et al., 2012). The up-regulation
of CNS miRNA-155 has also been asso-
ciated with infection by Bornavirus
(Bornaviridae; Group V, negative-
sense ssRNA) that causes an enzootic
encephalomyelitis, related to MS with
symptoms that include ataxia, ocular dis-







In recent efforts to neutralize NF-kB-
triggered, miRNA-mediated pathologies,
the use of anti-miRNA and anti-NF-kB
strategies have worked surprisingly well
both in vitro and in vivo in animal experi-
mentation. For example anti-miRNA-146a
and/or anti-miRNA-155 LNA-protected
oligonucleotides administered individu-
ally or as combinatorial cocktails exhibited
significant efficacy in cytokine-stressed
human primary neuronal-glial cell co-
cultures and in EAE in reducing aberrant
AD- and MS-related pro-inflammatory
signaling (Cui et al., 2010; Murugaiyan
et al., 2011; Lukiw et al., 2012; Lopez-
Ramirez et al., 2014). Very recently
miRNA-155 up-regulation that altered
junctional organization and permeability
of the blood-brain barrier in MS murine
models was prevented using inhibition of
endogenous miRNA-155 (Lopez-Ramirez
et al., 2014; Kamphuis et al., 2015). Equally
efficacious appear to be the use of anti-NF-
kB remedial strategies; the current number
of NF-kB inhibitors now exceeds 900 and
the use of combined anti-miRNA and NF-
kB inhibitors, and how and when to use
them therapeutically, has been recently
addressed (Gilmore and Herscovitch,
2006; Lukiw, 2012a,b, 2013; Gibson,
2014). In our view pathogenic miRNA-
146a and miRNA-155 up-regulation in
several progressive immunodeficiency
and/or pro-inflammatory disorders of
the CNS indicates that (i) knowledge of
the disease mechanism in one neurolog-
ical disorder may shed some light on a
similar disease mechanism in a related
CNS disease; (ii) differential anti-miRNA
and/or anti-NF-kB therapeutic strategies,
perhaps using combinatorial cocktails,
should be useful in the clinical manage-
ment of neurological disorders such as
MS; and (iii) multiple NF-kB inhibitors,
perhaps combined with multiple anti-
miRNA oligonucleotides and current MS
pharmacological drugs including dimethyl
fumarate and steroids may be tailored
to suit each individual MS case in the
expanding arena of personalized medicine
(Lukiw, 2012a,b; Gotovac et al., 2014;
Harris and Sadiq, 2014; Latta et al., 2014).
CONCLUDING REMARKS
Our understanding of NF-kB-regulated
miRNAs and their abundance and com-
plexity are revolutionizing our perceptions
and ideas on gene expression in CNS aging
and disease. It is our opinion that (i) pro-
gressive inflammatory neurodegeneration
in MS involves NF-kB-regulated miRNA-
146a and miRNA-155 and perhaps other
pathogenic miRNAs which are inducible;
(ii) targeting of inflammation-relevant gene
expression by miRNA-146a and/or miRNA-
155 suggest pathogenic pathways of MS
may be in common with other kinds of
human CNS degenerations; (iii) altered
miRNA expression patterns in MS may be
useful both diagnostically and in the design
of novel therapeutic approaches; and (iv)
anti-miRNA-146a, anti-miRNA-155, anti-
NF-kB and perhaps anti-viral drugs, either
alone or in combination with currently
prescribed MS anti-inflammatory drugs,
should open new avenues for future MS
research and therapeutic strategies useful in
the clinical management of MS and other
CNS disorders with a progressive inflamma-
tory and degenerative component.
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